Search

Your search keyword '"Maroie Barkati"' showing total 72 results

Search Constraints

Start Over You searched for: Author "Maroie Barkati" Remove constraint Author: "Maroie Barkati" Topic business.industry Remove constraint Topic: business.industry
72 results on '"Maroie Barkati"'

Search Results

1. PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study

2. EPV113/#323 Prognostic factors and oncologic outcomes for patients treated with adjuvant chemotherapy and vaginal vault brachytherapy for stage I endometrial serous carcinomas

3. Performance of an integrated multimodality image guidance and dose-planning system supporting tumor-targeted HDR brachytherapy for prostate cancer

4. A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer

5. MRI-based interstitial brachytherapy for vaginal tumors: A multi-institutional study on practice patterns, contouring, and consensus definitions of target volumes

6. DEVIL, VAAD and vLSC constitute a spectrum of HPV-independent, p53-independent intra-epithelial neoplasia of the vulva

7. Primary Endpoint Analysis of a Randomized Phase III Trial of Hypofractionated vs. Conventional Post-Prostatectomy Radiotherapy: NRG Oncology GU003

8. Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer

9. The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients

10. Quality of Life: A Prospective Randomized Trial of Palliative Volumetric Arc Therapy Versus 3-Dimensional Conventional Radiation Therapy

11. Neoadjuvant radiotherapy and brachytherapy in endometrial cancer with gross cervical involvement: a CHIRENDO research group study

12. A comparison of early prostate-specific antigen decline between prostate brachytherapy and different fractionation of external beam radiation—Impact on biochemical failure

14. OC-0038 Outcomes in focal vs. dose-painted salvage HDR brachytherapy for locally recurrent prostate cancer

15. PO-0177 A new software for designing patient-specific sleeves for the Montreal split-ring applicator

16. In Vivo Confirmation of Prostate Tumor Burden During HDR Brachytherapy With a Combined Raman Spectroscopy and MRI Radiomics Approach

17. PO-1128: Oncologic outcomes of cervical cancer using FIGO 2018 staging in the era of modern radiation therapy

18. MRI/PET Directed and TRUS/EM Guided Prostate Tumor Targeted HDR Brachytherapy: Performance of a Prototype System

19. Analysis of PSA Kinetics and Late Treatment Related Toxicity in a Phase 2 Randomized Pilot Study Comparing High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer

20. Clinical Applications of MRI in Radiotherapy Planning

21. PP-0156 HDR and LDR comparison as monotherapy in localized prostate cancer: PSA kinetic and late toxicity

22. Randomized Controlled Trial of PSMA PET/CT Guided Intensification of Radiotherapy for Prostate Cancer: Detection Rates and Impact on Radiotherapeutic Management

23. 15: Acura Analysis of PSA Kinetics and Late Treatment Related Toxicity in a Phase 2 Randomized Pilot Study Comparing High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer

24. 199 The Clinical Significance of Bone Mineral Density Changes Following Long Term Androgen Deprivation Therapy in Prostate Cancer Patients Enrolled in the PCS V Trial

25. 41 Partnership Initiative for the Evaluation of Technical Innovation in Radiotherapy (PERA): Pilot Performance of a Novel Trial Methodology

26. 115 Optimal Hypofractionated Rectal Dose-Volume Constraint from the Prostate Cancer Patients of the PCS V Trial

27. 125 Rectal Wall Versus Whole Rectum Dose: Which Volume Better Predicts Gastrointestinal Toxicity from Prostate External Beam Radiotherapy?

28. Prognostic Assessment of Interim FDG-PET in Esophageal Cancer Treated with Chemoradiation with or without Surgery

29. Optimal Hypofractionated Rectal Dose-Volume Constraint From The Prostate Cancer Patients of The PCS V Trial

30. The Clinical Significance of Bone Mineral Density Changes Following Long Term Androgen Deprivation Therapy in Prostate Cancer Patients Enrolled in the PCS V Trial

31. Magnetic resonance imaging for prostate bed radiotherapy planning: An inter- and intra-observer variability study

32. MP05-08 THE IMPACT OF BASELINE SERUM TESTOSTERONE ON THE RISK OF BIOCHEMICAL FAILURE AFTER DEFINITIVE RADIATION THERAPY FOR PROSTATE CANCER: MORE FAVOURABLE ONCOLOGICAL OUTCOMES IN HYPOGONADAL INVIDIDUALS

33. External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer

34. Pre-radiotherapy PSA progression is a negative prognostic factor in prostate cancer patients using 5‑alpha-reductase inhibitors

35. Vaginal Epithelioid Angiosarcoma

36. A Phase II Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Low-Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer

37. Rectal Wall vs. Whole Rectum Dose: Which Volume Better Predicts Gastrointestinal Toxicity from Prostate External Beam Radiotherapy?

38. Hemoglobin Level in Cervical Cancer

39. Prostate-specific antigen density is predictive of outcome in suboptimal prostate seed brachytherapy

40. Changes in periprostatic adipose tissue induced by 5α-reductase inhibitors

42. Adjuvant Chemotherapy and Vaginal Vault Brachytherapy With or Without Pelvic Radiotherapy for Stage 1 Papillary Serous or Clear Cell Endometrial Cancer

43. High-Dose-Rate Brachytherapy as a Monotherapy for Favorable-Risk Prostate Cancer: A Phase II Trial

44. Phase 3 Study of Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Adenocarcinoma of the Prostate

46. EP-1774: Randomized phase II trial of IGRT with or without HDR boost in intermediate-risk prostate cancer

47. Patterns of Failure and Treatment-Related Toxicity in Advanced Cervical Cancer Patients Treated Using Extended Field Radiotherapy With Curative Intent

48. Hypofractionated, dose escalation radiotherapy for high-risk prostate cancer: The primary endpoint of a group led phase III trial. (PCS5)

49. Single-fraction high-dose-rate brachytherapy using real-time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: dosimetrics and early clinical results

50. Impact of visceral fat volume and fat density on biochemical outcome after radical prostatectomy and postoperative radiotherapy

Catalog

Books, media, physical & digital resources